Selank
Also known as: TP-7
Russian-developed analog of tuftsin marketed (in Russia) as an anxiolytic. Mechanism involves modulation of GABA and stress-response pathways.
Limited human and mechanistic evidence
Selank has small Russian clinical literature and mechanistic/anxiolytic studies, but lacks broad Western regulatory review or large independent trials.
Limited human pharmacology or small clinical evidence.
Evidence basis
- Small clinical comparison literature
- Mechanistic anxiolytic reviews
- Preclinical stress/anxiety models
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Category hub
Open the category page for the full comparison table and FAQ.